CVRX
CVRx, Inc. [CVRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CVRX Stock Summary
Top 10 Correlated Stocks
CVRX
In the News
CVRX Financial details
Company Rating
-
Market Cap
360.58M
Income
-41.2M
Revenue
39.3M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
200
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-13.74
Forward P/E
-
PEG
69.39
P/S
16.64
P/B
7.06
P/C
-
P/FCF
-17.04
Quick Ratio
12.06
Current Ratio
13.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.98
EPS next Y
-
EPS next Q
-
EPS this Y
-1.49%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
21.23%
Revenue last 5Y
44.41%
Revenue Q/Q
7.55%
EPS Q/Q
2.33%
-
-
-
-
SMA20
-3.6%
SMA50
-50.92%
SMA100
-52.1%
Inst Own
-
Inst Trans
-
ROA
-40%
ROE
-45%
ROC
-0.45%
Gross Margin
83%
Oper. Margin
-128%
Profit Margin
-121%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.93-33.135
52W High
-80.79%
52W Low
-20.75%
RSI
43.3
Rel Volume
3.39
Avg Volume
148.02K
Volume
501.35K
Perf Week
-15.24%
Perf Month
-48.33%
Perf Quarter
-53.11%
Perf Half Y
-55.35%
-
-
-
-
Beta
1.23
-
-
Volatility
0.99%, 1.51%
Prev Close
2.42%
Price
6.34
Change
16.54%
Company Profile
- Volume Average 148.02K
- Market Capitalization 360.58M
- Employee 200
- CEO Mr. Kevin Hykes
- Headquarters Minneapolis,MN,US
- IPO Date 2021-06-30
-
Website
https://www.cvrx.com 
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
